Journal issues > Issue 7, November 2020 > Long-term treatment-free molecular remission in a FIP1L1-PDGFRA positive myeloid/lymphoid neoplasm with eosinophilia after Imatinib discontinuation

Long-term treatment-free molecular remission in a FIP1L1-PDGFRA positive myeloid/lymphoid neoplasm with eosinophilia after Imatinib discontinuation

By: D. Papazoglou MD, A. Salaroli MD, P. Heimann MD, PhD, P. Lewalle MD, PhD, D. Bron MD, PhD

SUMMARY

A 47-year-old patient was diagnosed with FIP1L1-PDGFRA-positive myeloid/lymphoid neoplasm with eosinophilia (F/P+ MLN-eo) and was successfully treated with Imatinib, achieving a sustained molecular treatment free remission (TFR) persisting three years after discontinuation.

(BELG J HEMATOL 2020;11(7):320-4)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top